Literature DB >> 20104635

Management of perioperative hypertensive urgencies with parenteral medications.

Kartikya Ahuja1, Mitchell H Charap.   

Abstract

BACKGROUND: Hypertension is the major risk factor for cardiovascular (CV) disease such as myocardial infarction (MI) and stroke. This risk is well known to extend into the perioperative period. Although most perioperative hypertension can be managed with the patient's outpatient regimen, there are situations in which oral medications cannot be administered and parenteral medications become necessary. They include postoperative nil per os status, severe pancreatitis, and mechanical ventilation. This article reviews the management of perioperative hypertensive urgency with parenteral medications.
METHODS: A PubMed search was conducted by cross-referencing the terms "perioperative hypertension," "hypertensive urgency," "hypertensive emergency," "parenteral anti-hypertensive," and "medication." The search was limited to English-language articles published between 1970 and 2008. Subsequent PubMed searches were performed to clarify data from the initial search.
RESULTS: As patients with hypertensive urgency are not at great risk for target-organ damage (TOD), continuous infusions that require intensive care unit (ICU) monitoring and intraarterial catheters seem to be unnecessary and a possible misuse of resources.
CONCLUSIONS: When oral therapy cannot be administered, patients with hypertensive urgency can have their blood pressure (BP) reduced with hydralazine, enalaprilat, metoprolol, or labetalol. Due to the scarcity of comparative trials looking at clinically significant outcomes, the medication should be chosen based on comorbidity, efficacy, toxicity, and cost.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20104635     DOI: 10.1002/jhm.629

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  5 in total

Review 1.  Advances in management of acute hypertension: a concise review.

Authors:  David B Tulman; Stanislaw P A Stawicki; Thomas J Papadimos; Claire V Murphy; Sergio D Bergese
Journal:  Discov Med       Date:  2012-05       Impact factor: 2.970

2.  Simultaneous Quantitation of Clevidipine and Its Active Metabolite H152/81 in Human Whole Blood by LC-MS/MS: Application to Bioequivalence Study.

Authors:  Pengfei Li; Haitang Wu; Zhixia Zhao; Ping Du; Haitong Xu; Hongchuan Liu; Yu Zhou; Weiyue Yu; Hao Li; Lihong Liu
Journal:  Front Chem       Date:  2022-04-07       Impact factor: 5.545

Review 3.  Perioperative hypertension: defining at-risk patients and their management.

Authors:  Susan F Lien; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

4.  Acute kidney injury induces high-sensitivity troponin measurement changes after cardiac surgery.

Authors:  Amr S Omar; Khaled Mahmoud; Samy Hanoura; Hany Osman; Praveen Sivadasan; Suraj Sudarsanan; Yasser Shouman; Rajvir Singh; Abdulaziz AlKhulaifi
Journal:  BMC Anesthesiol       Date:  2017-01-31       Impact factor: 2.217

5.  Perioperative acute hypertension-role of Clevidipine butyrate.

Authors:  Lakshmi N Kurnutala; Suren Soghomonyan; Sergio D Bergese
Journal:  Front Pharmacol       Date:  2014-08-27       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.